Zimmer Biomet Holdings, Inc. (ZBH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Core Insights - The company expresses high confidence in achieving a growth rate of approximately 6% in Q3, as previously indicated in their August 7 commentary [1] - The company anticipates that Q4 may experience a softer performance compared to Q3 [1] Group 1 - The company plans for an acceleration in growth as implied in their 2025 guidance [1] - The CEO emphasizes the importance of maintaining public commentary and refraining from speculation beyond the disclosed information [1] - The company will be surprised if the growth rate does not reach at least 6% in Q3, indicating strong expectations for performance [1]